Integrated Strategies For Accelerating Your Molecule From Discovery to IND and Beyond

The early drug development roadmap from discovery to preclinical IND and onwards can be difficult to navigate. That means, understanding each critical step, their timings, and potential risks at each stage requires extensive expertise.

In this presentation, senior leaders from Charles River and Quotient Sciences will discuss how this collaboration helps customers by bringing expert knowledge, removing obstacles from the critical path, reducing development risks, and shortening the pathway to clinical development. The presentation will cover.

• Building a strategy to drive hit identification through to pre-clinical candidate identification
• Creating bespoke solutions for partners illustrated through case studies
• Derisking the lead optimization stages and therefore improving the chances of the best lead candidate selection
• Seamlessly managing the integration of discovery and development activities
• How to select a synthetic route which is safe, regulatory compliant, and economically viable
• Managing risks around GMP scale up and importance of timely development of robust analytical methods.  

                 
Combined, Charles River and Quotient Sciences have over 100 years of experience in the drug development space, working with molecules across all stages of development. You'll hear case studies highlighting how an integrated program provides customers with a full set of deliverables needed to be “clinic ready” and improve the chances of clinical success.

Don't miss out on our expert presentation and a complimentary lunch seminar - register to attend today!

*We reserve the right, at our sole discretion, to deny registration or remove any individual who is not a confirmed current or potential client/partner of Quotient Sciences.

Register now